Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity
详细信息 查看全文
- 作者：Jorge Schettini (2)
Amritha Kidiyoor (2)
Dahlia M. Besmer (2)
Teresa L. Tinder (2)
Lopamudra Das Roy (2)
Joseph Lustgarten (3)
Sandra J. Gendler (4)
Pinku Mukherjee (1) - 关键词：Immunoconjugates ; Cancer vaccines ; Immune response to cancer ; Immunotherapy ; Pancreatic cancer
- 刊名：Cancer Immunology, Immunotherapy
- 出版年：2012
- 出版时间：November 2012
- 年：2012
- 卷：61
- 期：11
- 页码：2055-2065
- 全文大小：538KB
- 参考文献：1. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373(9668):1033鈥?040 CrossRef
2. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147鈥?157 CrossRef
3. Cartron G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor / FcgammaRIIIa gene. Blood 99(3):754鈥?58 CrossRef
4. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940鈥?947 CrossRef
5. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275鈥?90 CrossRef
6. Clynes RA et al (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443鈥?46 CrossRef
7. Sulica A et al (2001) Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol 20(3鈥?):371鈥?14 CrossRef
8. Peipp M et al (2008) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112(6):2390鈥?399 CrossRef
9. Leidi M et al (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182(7):4415鈥?422 CrossRef
10. Karagiannis SN et al (2007) IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179(5):2832鈥?843
11. Khan KD et al (2006) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin鈥檚 lymphoma. Clin Cancer Res 12(23):7046鈥?053 CrossRef
12. Umana P et al (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176鈥?80 CrossRef
13. Orange JS, Ballas ZK (2006) Natural killer cells in human health and disease. Clin Immunol 118(1):1鈥?0 CrossRef
14. Bowles JA, Weiner GJ (2005) CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304(1鈥?):88鈥?9 CrossRef
15. Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97(1):14鈥?2 CrossRef
16. Moga E et al (2008) NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 36(1):69鈥?7 CrossRef
17. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5(6):471鈥?84 CrossRef
18. Ballas ZK (2007) Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res 39(1鈥?):15鈥?1 CrossRef
19. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709鈥?60 CrossRef
20. Roda JM, Parihar R, Carson WE III (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619鈥?627
21. Krieg AM et al (2004) Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27(6):460鈥?71 CrossRef
22. Link BK et al (2006) Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29(5):558鈥?68 CrossRef
23. Andoniou CE et al (2005) Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 6(10):1011鈥?019 CrossRef
24. Adachi O et al (1998) Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 9(1):143鈥?50 CrossRef
25. Tinder TL et al (2008) MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 181(5):3116鈥?125
26. Mukherjee P et al (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182(1):216鈥?24 CrossRef
27. Besmer DM et al (2011) Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 71(13):4432鈥?442 CrossRef
28. Roy LD et al (2011) MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30(12):1449鈥?459 CrossRef
29. Taylor-Papadimitriou J et al (1981) Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28(1):17鈥?1 CrossRef
30. Grosso JF et al (2004) MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. J Immunol 173(3):1721鈥?730
31. Vitetta ES, Hart DA, Forman J (1978) Relationship between trinitrophenol and H-2 antigens on trinitrophenyl-modified spleen cells. III. Quantitative aspects of trinitrophenol binding on cells treated with trinitrobenzene sulfonic acid. J Immunol 121(3):997鈥?001
32. Trevani AS et al (2003) Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 33(11):3164鈥?174 CrossRef
33. Sfondrini L et al (2002) Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 16(13):1749鈥?754 CrossRef
34. Sharma S et al (2008) Systemic targeting of CpG鈥揙DN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res 68(18):7530鈥?540 CrossRef
35. Zafir-Lavie I, Michaeli Y, Reiter Y (2007) Novel antibodies as anticancer agents. Oncogene 26(25):3714鈥?733 CrossRef
36. Sanjuan MA et al (2006) CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 172(7):1057鈥?068 CrossRef
37. Liese J, Schleicher U, Bogdan C (2007) TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur J Immunol 37(12):3424鈥?434 CrossRef
38. Krieg AM (2003) CpG motifs: the active ingredient in bacterial extracts? Nat Med 9(7):831鈥?35 CrossRef
39. Zhu P et al (2009) Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells. J Biol Chem 284(34):22878鈥?2887 CrossRef
40. Trieu A et al (2009) TLR9-independent effects of inhibitory oligonucleotides on macrophage responses to / S. / typhimurium. Immunol Cell Biol 87(3):218鈥?25 CrossRef
41. Hokeness-Antonelli KL et al (2007) IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J Immunol 179(9):6176鈥?183
42. Rutz M et al (2004) Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34(9):2541鈥?550 CrossRef
43. Sivori S et al (2006) Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol 36(4):961鈥?67 CrossRef
44. Lauzon NM, Mian F, Ashkar AA (2007) Toll-like receptors, natural killer cells and innate immunity. Adv Exp Med Biol 598:1鈥?1 CrossRef - 作者单位：Jorge Schettini (2)
Amritha Kidiyoor (2)
Dahlia M. Besmer (2)
Teresa L. Tinder (2)
Lopamudra Das Roy (2)
Joseph Lustgarten (3)
Sandra J. Gendler (4)
Pinku Mukherjee (1)
2. Department of Biology, University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC, 28223, USA
3. Department of Immunology, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ, 85259, USA
4. Department of Biochemistry and Molecular Biology, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ, 85259, USA
1. Irwin Belk Distinguished Scholar for Cancer Research, Department of Biology, University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC, 28223, USA - ISSN：1432-0851
文摘
Monoclonal antibodies (mAbs) against tumor-associated antigens are useful anticancer agents. Antibody-dependent cellular cytotoxicity (ADCC) is one of the major mechanisms responsible for initiating natural killer cell (NK)-mediated killing of tumors. However, the regulation of ADCC via NK cells is poorly understood. We have investigated the cytolytic activity of NK cells against pancreatic cancer cells that were coated with an antibody directed against the human tumor antigen, Mucin-1 designated HMFG-2, either alone or conjugated to CpG oligodeoxynucleotide (CpG ODN). Conjugated antibodies were tested for their ability to elicit ADCC in vitro and in vivo against pancreatic cancer cells. NK cells cultured in the presence of immobilized CpG ODN, HMFG-2 Ab, or CpG ODN-conjugated HMFG-2 Ab were able to up-regulate perforin similarly. Interestingly, a significant higher ADCC was observed when CpG ODN-conjugated HMFG-2-coated tumor cells were co-cultured with NK cells compared to unconjugated HMFG-2 Ab or CpG ODN alone. Moreover, MyD88-deficient NK cells can perform ADCC in vitro. Furthermore, intratumoral injections of CpG ODN-conjugated HMFG-2 induced a significant reduction in tumor burden in vivo in an established model of pancreatic tumor in nude mice compared to CpG ODN or the HMFG-2 alone. Depletion of macrophages or NK cells before treatment confirmed that both cells were required for the anti-tumor response in vivo. Results also suggest that CpG ODN and HMFG-2 Ab could be sensed by NK cells on the mAb-coated tumor cells triggering enhanced ADCC in vitro and in vivo.